Rybodyn utilizes proprietary RyboCypher™ technology to sequence and analyze the dark proteome, revealing previously overlooked therapeutic targets. This platform integrates novel RNA sequencing with AI models to predict proteins encoded by non-coding RNAs. The company translates these cryptic targets into a pipeline of antibody-based drug candidates for next-generation immunotherapies.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFounders
Product
Problem
Many diseases, including solid tumors and autoimmune disorders, lack effective targeted therapies due to the difficulty in identifying and validating disease-specific targets within the "dark proteome," the portion of the proteome that is poorly understood. This lack of validated targets limits the development of novel immunotherapies.
Solution
RyboDyn is developing targeted immunotherapies by identifying and validating previously inaccessible disease-specific targets within the dark proteome. Their proprietary platform facilitates the discovery and optimization of first-in-class therapeutics, addressing the unmet need for effective treatment options in areas with limited or no existing therapies. By focusing on the dark proteome, RyboDyn aims to unlock novel therapeutic avenues for solid tumors and autoimmune diseases. This approach allows for the development of highly specific immunotherapies with potentially improved efficacy and reduced off-target effects.
Target Audience
RyboDyn's primary target audience includes pharmaceutical companies and research institutions seeking novel therapeutic targets and innovative immunotherapy approaches for solid tumors and autoimmune diseases.
Features
- Proprietary platform for identifying and validating disease-specific targets within the dark proteome
- Focus on developing first-in-class immunotherapies
- Target discovery and optimization capabilities
- Emphasis on solid tumors and autoimmune diseases